“We need to optimize our SOPs at the beginning, we need to have transparency with our oncologists, and our pathologists, and the diagnostics labs all of this needs to be done, which is improvement upstream and then when you get the result you get a result that has many mutations, but how does that affect what your patient needs and how do you provide that information.” –Manoja Lecamwasam, PhD